NCT06888479Not yet recruitingPhase 3
Optimal Timing of Hepatitis B Vaccination After Transplants
Optimal Timing of Hepatitis B Vaccination After Transplants: a Randomized Clinical Study
Source: ClinicalTrials.gov · Last updated 21 Mar 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The investigators aim to perform a randomized clinical trial to determine the optimal timing of hepatitis B vaccination after hematopoietic cell transplantation (HCT) through evaluating the immunity effect of two different vaccination schedules (initiated at 3 or 6 months after transplantation) in patients with different immune reconstitution status.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 1500 (estimated)
- First submitted
- 14 Jan 2025
- Start date
- 1 Jun 2025
- Primary completion date
- 1 Jun 2028
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Diseases
- Hepatitis B
- NCT number
- NCT06888479
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 1500
- From 1 Jun 2025 to the primary completion date, 1 Jun 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Donors' HBV-DNA or HBsAg are positive;
- Patients' HBV-DNA or HBsAg are positive before transplantation or \< 3 months after transplantation;
- Patients who are unable to comply with the research treatments and monitoring requirements due to mental or other medical conditions;
Other
- Multiple transplantations;
- Patients who are ineligible for the study due to other reasons which would cause unacceptable risks to the patients.
Who the study is looking for
- Patients must be ≥ 16 years old;
- Patients receiving hematopoietic cell transplantation;
- Patients achieving complete molecular remission;
- Patients or their guardians have to sign an informed consent form before the start of the research procedure.
Age in the registry: 16 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institute of Hematology & Blood Diseases Hospital Coordinator of this site? Confirm its status | Tianjin | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.